September 28, 2022
AstraZeneca’s COVID-19 antibody cocktail Evusheld (tixagevimab/cilgavimab) holds the potential of becoming a good option to prevent COVID-19 in patients who cannot get adequate immune responses from vaccines, a vice president of the company's Japan arm said on September 26. Speaking...read more